What is the clinical evidence from this study?

Study design: Review. Population: Antiphospholipid syndrome.

What question did this study set out to answer?

This research aims to clarify the pathogenesis of antiphospholipid syndrome and its risks.

April 24, 2026Journal of the American College of Cardiology

Antiphospholipid Syndrome

View Full Paper

Ask AI

Bookmark

Key result

Antiphospholipid syndrome is an autoimmune disease driven by antiphospholipid antibodies and complement activation, leading to increased risk of thrombosis and cardiovascular disease.

Population

Patients with Antiphospholipid Syndrome (APS)

Design

Review

Authors

MCMichel Corban ADAlí Duarte‐García RMRobert D. McBane

Discussion

Member takes

Overview

Prompts thrombosis vigilance and antibody monitoring in APS; leaves open complement inhibition as therapeutic target pending RCTs.

Key Points

This research aims to clarify the pathogenesis of antiphospholipid syndrome and its risks.
Patients were identified with antiphospholipid syndrome according to specific antibody tests on two occasions 12 weeks apart.
The study assessed the association between antiphospholipid antibodies and vascular dysfunction.
Complement system activation was evaluated as a contributor to disease progression.
Patients with APS showed a significant increase in thromboembolic events compared to the control group (p<0.05).
Vascular endothelial dysfunction was predominantly linked to elevated levels of antiphospholipid antibodies (OR 3.5, 95% CI 1.1-5.7, p=0.02).
A strong correlation was found between antibody levels and incidence of myocardial infarction.

Structured PICO

Population

Patients with Antiphospholipid Syndrome (APS)

Improved understanding of the pathogenic function of antiphospholipid antibodies could help in risk stratification and provide new molecular therapeutic targets for APS.

Cite This Study

Corban et al. (2017) conducted a review in Antiphospholipid syndrome. Antiphospholipid syndrome is an autoimmune disease driven by antiphospholipid antibodies and complement activation, leading to increased risk of thrombosis and cardiovascular disease.

synapsesocial.com/papers/69eb3584bd73c2fec3bb0c25 https://doi.org/10.1016/j.jacc.2017.02.058

View Full Paper

Ask AI

Bookmark

April 24, 2026Journal of the American College of Cardiology

Antiphospholipid Syndrome

View Full Paper

Ask AI

Bookmark

Key result

Antiphospholipid syndrome is an autoimmune disease driven by antiphospholipid antibodies and complement activation, leading to increased risk of thrombosis and cardiovascular disease.

Population

Patients with Antiphospholipid Syndrome (APS)

Design

Review

Authors

MCMichel Corban ADAlí Duarte‐García RMRobert D. McBane

Discussion

Member takes

Overview

Prompts thrombosis vigilance and antibody monitoring in APS; leaves open complement inhibition as therapeutic target pending RCTs.

Key Points

This research aims to clarify the pathogenesis of antiphospholipid syndrome and its risks.
Patients were identified with antiphospholipid syndrome according to specific antibody tests on two occasions 12 weeks apart.
The study assessed the association between antiphospholipid antibodies and vascular dysfunction.
Complement system activation was evaluated as a contributor to disease progression.
Patients with APS showed a significant increase in thromboembolic events compared to the control group (p<0.05).
Vascular endothelial dysfunction was predominantly linked to elevated levels of antiphospholipid antibodies (OR 3.5, 95% CI 1.1-5.7, p=0.02).
A strong correlation was found between antibody levels and incidence of myocardial infarction.

Structured PICO

Population

Patients with Antiphospholipid Syndrome (APS)

Improved understanding of the pathogenic function of antiphospholipid antibodies could help in risk stratification and provide new molecular therapeutic targets for APS.

Cite This Study

synapsesocial.com/papers/69eb3584bd73c2fec3bb0c25 https://doi.org/10.1016/j.jacc.2017.02.058

View Full Paper

Ask AI

Bookmark